UA100545C2 - Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт - Google Patents

Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт

Info

Publication number
UA100545C2
UA100545C2 UAA201009871A UAA201009871A UA100545C2 UA 100545 C2 UA100545 C2 UA 100545C2 UA A201009871 A UAA201009871 A UA A201009871A UA A201009871 A UAA201009871 A UA A201009871A UA 100545 C2 UA100545 C2 UA 100545C2
Authority
UA
Ukraine
Prior art keywords
protein kinase
kinase inhibitors
akt protein
hydroxylated
pyrimidyl cyclopentanes
Prior art date
Application number
UAA201009871A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джозеф Р. Бенсік
Джеймс Ф. Блейк
Ніколас С. Каллан
Ян С. Мітчелл
Кейт Лі Спенсер
Денгмінг Хіао
Руі Ху
Крістін Чабот
Стівен До
Джун Ліанг
Браян Сафіна
Біронг Жанг
Original Assignee
Еррей Біофарма Інк.
Дженентек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еррей Біофарма Інк., Дженентек, Інк. filed Critical Еррей Біофарма Інк.
Publication of UA100545C2 publication Critical patent/UA100545C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение описывает соединения, в том числе их фармацевтически приемлемые соли, которые соответствуют Формуле I: I, а также применение соединений согласно изобретению как ингибиторов протеинкиназы АКТ, а также для лечения гиперпролиферативных заболеваний, таких как рак.
UAA201009871A 2008-01-09 2009-09-01 Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт UA100545C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2009208P 2008-01-09 2008-01-09
PCT/US2009/030610 WO2009089459A1 (en) 2008-01-09 2009-01-09 Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors

Publications (1)

Publication Number Publication Date
UA100545C2 true UA100545C2 (ru) 2013-01-10

Family

ID=40552865

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201009871A UA100545C2 (ru) 2008-01-09 2009-09-01 Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт

Country Status (18)

Country Link
US (1) US8835434B2 (ru)
EP (1) EP2247578B1 (ru)
JP (1) JP5346345B2 (ru)
KR (1) KR101624753B1 (ru)
CN (1) CN101932564B (ru)
AU (1) AU2009204025B2 (ru)
BR (1) BRPI0906798A2 (ru)
CA (1) CA2711699A1 (ru)
CR (1) CR11601A (ru)
EC (1) ECSP10010389A (ru)
ES (1) ES2422733T3 (ru)
IL (1) IL206575A0 (ru)
MA (1) MA32183B1 (ru)
NZ (1) NZ586346A (ru)
RU (1) RU2504542C2 (ru)
UA (1) UA100545C2 (ru)
WO (1) WO2009089459A1 (ru)
ZA (1) ZA201004769B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801955B (zh) * 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP5608097B2 (ja) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピロロピリジン
CN101970415A (zh) 2008-01-09 2011-02-09 阵列生物制药公司 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
PL2861583T3 (pl) * 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
MX353041B (es) * 2012-05-17 2017-12-18 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y métodos de este.
MX2020009462A (es) 2013-11-15 2021-08-31 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano.

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885035A (en) 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
JPS562968A (en) 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
JPS6270A (ja) 1985-03-07 1987-01-06 Sankyo Co Ltd シクロペンタ〔ｄ〕ピリミジン誘導体
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
DK0664291T3 (da) 1992-10-05 2000-10-30 Ube Industries Pyrimidinforbindelse
US5750545A (en) 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP0775120B1 (en) 1994-08-13 2003-06-04 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (ru) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Замещенные 3-циан хинолины
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
EP0993437B1 (en) 1997-07-01 2006-11-08 Warner-Lambert Company Llc 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
PT993439E (pt) 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
DE69943144D1 (de) 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
WO2000042022A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
CA2355374A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
EP1144371B1 (en) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
BR9916894A (pt) 1999-01-13 2001-11-20 Warner Lambert Co ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
WO2001005390A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
JP2003504399A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
PL352712A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
EA005818B1 (ru) 2000-07-19 2005-06-30 Уорнер-Ламберт Компани Сложные эфиры фениламинобензгидроксамовых кислот
CA2420003A1 (en) 2000-08-25 2002-03-07 Derick Dale Winkle Process for making n-aryl-anthranilic acids and their derivatives
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
JP2004528349A (ja) 2001-04-30 2004-09-16 グラクソ　グループ　リミテッド 副腎皮質刺激ホルモン放出因子（ｃｒｆ）のアンタゴニストとしての縮合ピリミジン類
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US20030216460A1 (en) 2002-03-13 2003-11-20 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984613B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1496896A4 (en) 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
JP4394959B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
JP4394961B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤としての融合キノキサリン誘導体
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003094918A1 (en) 2002-05-10 2003-11-20 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
EP1558586B1 (en) 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
EP1656354B1 (en) 2003-08-12 2007-09-26 F.Hoffmann-La Roche Ag Tetrahydroquinazoline derivatives as cfr antagonists
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
NO320062B1 (no) * 2003-11-19 2005-10-17 New Interaction Devices And Te Anordning til a detektere naerhet mellom et forste objekt (malobjekt) og et annet objekt (referanseobjekt), samt tegne-, skrive- og/eller pekeredskap for datapresentasjon etc.
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP2008531542A (ja) 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 抗癌剤として有用な二環式複素芳香族誘導体
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
AR054485A1 (es) 2005-06-21 2007-06-27 Cancer Rec Tech Ltd ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
WO2007042299A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
PE20071164A1 (es) 2005-12-28 2008-01-11 Takeda Pharmaceutical Compuestos heterociclico fusionado como antagonista del receptor mineralocorticoide
EP2013206A1 (en) 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
KR20150041164A (ko) 2006-07-06 2015-04-15 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008003697A1 (en) 2006-07-06 2008-01-10 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Ａｌｋ−５阻害剤としてのピリミジン誘導体
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
CN101801955B (zh) 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷

Also Published As

Publication number Publication date
CA2711699A1 (en) 2009-07-16
KR20100118110A (ko) 2010-11-04
AU2009204025B2 (en) 2014-02-20
IL206575A0 (en) 2010-12-30
JP2011509308A (ja) 2011-03-24
CR11601A (es) 2010-08-19
ES2422733T3 (es) 2013-09-13
EP2247578A1 (en) 2010-11-10
KR101624753B1 (ko) 2016-05-26
NZ586346A (en) 2012-02-24
ZA201004769B (en) 2011-12-28
US20110065716A1 (en) 2011-03-17
RU2504542C2 (ru) 2014-01-20
ECSP10010389A (es) 2010-11-30
CN101932564A (zh) 2010-12-29
JP5346345B2 (ja) 2013-11-20
CN101932564B (zh) 2012-12-26
EP2247578B1 (en) 2013-05-22
WO2009089459A1 (en) 2009-07-16
MA32183B1 (fr) 2011-04-01
BRPI0906798A2 (pt) 2015-07-14
RU2010132911A (ru) 2012-02-20
US8835434B2 (en) 2014-09-16
AU2009204025A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
IN2014KN02886A (ru)
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
MX2009014013A (es) Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
WO2009006567A3 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TN2011000293A1 (en) Protein kinase inhibitors
UA100544C2 (ru) Гидроксилированный пиримидилциклопентан как ингибитор протеинкиназы акт
MX2011012037A (es) Compuestos de heteroarilo como inhibidores de pikk.
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX346186B (es) Inhibidores de proteina cinasas.
MX2012004780A (es) Inhibidores de akt.
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA104410C2 (ru) Пиримидилциклопентаны как ингибиторы протеинкиназ акт
MX2012006897A (es) Compuestos heterociclicos como inhibidores de janus cinasa.
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease